A Review on Brain Metastases Prognostic Scoring Systems

Abstract

Brain metastases (BMs) represent the most common intracranial tumors, and nearly 25% of all cancer patients are diagnosed with this poor prognostic disease condition somewhere during their treatment course. Depending on the potential patient's general well-being status, the main prevailing treatment options typically incorporate palliative radiotherapy, chemotherapy, targeted agents, immunotherapy, best supportive care, and less frequently surgery in select patients. Past investigations demonstrated the probability to stratify BM patients into particular prognostic gatherings according to the credible combinations of multiple patients- and tumor-related features: the prognostic scoring systems. Such frameworks may serve usefully in the accurate prediction of survival outcomes and the appropriate selection of the best-fit treatment elective. In this present review, we intended to survey the advantages and disadvantages of the broadly recognized on-the-spot prognostic scoring systems for BMs and their clinical merits.